About Genenta Science
Genenta Science is a company based in Milan (Italy) founded in 2014 by Pierluigi Paracchi.. Genenta Science has raised $33.58 million across 4 funding rounds from investors including Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan. The company has 13 employees as of December 31, 2024. Genenta Science offers products and services including Temferon™. Genenta Science operates in a competitive market with competitors including Spark Therapeutics, AskBio, Unity Biotechnology, Zymeworks and Generation Bio, among others.
- Headquarter Milan, Italy
- Employees 13 as on 31 Dec, 2024
- Founders Pierluigi Paracchi
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genenta Science Spa Sponsored Adr
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-9.64 M23.43as on Dec 31, 2024
-
EBITDA
$-10.51 M16.81as on Dec 31, 2024
-
Total Equity Funding
$33.58 M (USD)
in 4 rounds
-
Latest Funding Round
$21.9 M (USD), Post-IPO
Mar 19, 2025
-
Investors
Mediobanca Private Banking
& 2 more
-
Employee Count
13
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genenta Science
Genenta Science is a publicly listed company on the NASDAQ with ticker symbol GNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Genenta Science
Genenta Science offers a comprehensive portfolio of products and services, including Temferon™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers therapeutic payloads to tumor microenvironment for cancer treatment.
Unlock access to complete
Funding Insights of Genenta Science
Genenta Science has successfully raised a total of $33.58M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.9 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $21.9M
-
First Round
First Round
(05 Mar 2015)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2025 | Amount | Post-IPO - Genenta Science | Valuation |
investors |
|
| Sep, 2019 | Amount | Series C - Genenta Science | Valuation | Qianzhan |
|
| Sep, 2017 | Amount | Series B - Genenta Science | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genenta Science
Genenta Science has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Industry trends and market analysis are provided by Qianzhan.
|
Founded Year | Domain | Location | |
|
Mediobanca Private Banking is focused on wealth management and investment banking.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genenta Science
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genenta Science
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genenta Science Comparisons
Competitors of Genenta Science
Genenta Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, AskBio, Unity Biotechnology, Zymeworks and Generation Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare liver and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Tumor-selective immunotherapies for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genenta Science
Frequently Asked Questions about Genenta Science
When was Genenta Science founded?
Genenta Science was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Genenta Science located?
Genenta Science is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Who is the current CEO of Genenta Science?
Pierluigi Paracchi is the current CEO of Genenta Science. They have also founded this company.
Is Genenta Science a funded company?
Genenta Science is a funded company, having raised a total of $33.58M across 4 funding rounds to date. The company's 1st funding round was a Series B of $8M, raised on Mar 05, 2015.
How many employees does Genenta Science have?
As of Dec 31, 2024, the latest employee count at Genenta Science is 13.
What does Genenta Science do?
Genenta Science was founded in 2014 in Milan, Italy, with operations centered on biotechnology. Lentivirus-based gene and cell therapies are developed for cancer treatment, targeting solid tumors, hematological malignancies, and glioblastoma. The lead candidate, Temferon, is utilized as a hematopoietic stem progenitor cell immuno-gene therapy. Tie2-expressing monocytes are also employed in immunotherapies for various cancers. Focus is maintained on advancing these therapies through clinical development.
Who are the top competitors of Genenta Science?
Genenta Science's top competitors include Spark Therapeutics, Generation Bio and AskBio.
What products or services does Genenta Science offer?
Genenta Science offers Temferon™.
Is Genenta Science publicly traded?
Yes, Genenta Science is publicly traded on NASDAQ under the ticker symbol GNTA.
Who are Genenta Science's investors?
Genenta Science has 3 investors. Key investors include Mediobanca Private Banking, ENEA Tech e Biomedical, and Qianzhan.
What is Genenta Science's ticker symbol?
The ticker symbol of Genenta Science is GNTA on NASDAQ.